Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis.
Boney CM., Moats-Staats BM., Stiles AD., D'Ercole AJ.
Animal Study, published in Endocrinology (1994) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Endocrinology (1994)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 7525256
- DOI
- 10.1210/endo.135.5.7525256
Abstract (original English)
Insulin-like growth factor-I (IGF-I) stimulates the differentiation of preadipocytes, but the expression of IGF-I and IGF-binding proteins (IGFBPs) during the course of adipogenesis has not been investigated. Using two in vitro models, primary mouse preadipocytes and the 3T3-L1 preadipocyte cell line stimulated to differentiate with IGF-I, we studied IGF and IGFBP expression before and during differentiation. Primary preadipocyte cultures expressed IGF-I, IGFBP-2, and IGFBP-4 messenger RNAs (mRNAs), and conditioned medium (CM) contained IGFBP-3 [approximately 46,000 mol wt (M(r))], IGFBP-4 (24,000 M(r)), and a 30,000 M(r) IGFBP identified by immunoblot as IGFBP-2. During differentiation, an additional approximately 34,000 M(r) form of IGFBP-2 was predominant, but IGFBP-2 mRNA decreased, suggesting that a mechanism other than steady state mRNA levels is regulating protein abundance in CM. Like primary cultures, undifferentiated 3T3-L1 cells expressed IGFBP-4 mRNA, but insignificant levels of IGF-I and IGFBP-2 mRNAs. 3T3-L1 cell CM contained IGFBP-3 and IGFBP-4, and with the addition of IGF-I, a 30,000 M(r) IGFBP was also present. This IGFBP was not recognized by antiserum to IGFBP-1, -2, -4, -5, or -6. During differentiation of 3T3-L1 cells, an approximately 34,000 M(r) form of IGFBP-2 was also present in CM. In summary, primary cultures of mouse preadipocytes and 3T3-L1 cells e
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.